Brokerages Set BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Target Price at $88.00

Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) have earned an average recommendation of “Moderate Buy” from the twenty-three brokerages that are currently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell recommendation, six have given a hold recommendation, fifteen have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $88.4091.

BMRN has been the topic of a number of analyst reports. Bank of America reduced their price objective on shares of BioMarin Pharmaceutical from $85.00 to $80.00 and set a “buy” rating on the stock in a research note on Tuesday, May 19th. Morgan Stanley boosted their target price on shares of BioMarin Pharmaceutical from $119.00 to $124.00 and gave the company an “overweight” rating in a report on Friday, August 7th. Piper Sandler increased their price target on BioMarin Pharmaceutical from $82.00 to $88.00 and gave the stock an “overweight” rating in a report on Monday. Barclays boosted their price objective on BioMarin Pharmaceutical from $105.00 to $111.00 and gave the company an “overweight” rating in a research note on Monday. Finally, Canaccord Genuity Group upped their target price on BioMarin Pharmaceutical from $111.00 to $114.00 and gave the company a “buy” rating in a research report on Monday, August 10th.

Institutional Trading of BioMarin Pharmaceutical

Several large investors have recently modified their holdings of the stock. Primecap Management Co. CA bought a new stake in shares of BioMarin Pharmaceutical during the second quarter worth about $811,962,000. Viking Global Investors LP lifted its position in BioMarin Pharmaceutical by 13.8% in the 2nd quarter. Viking Global Investors LP now owns 12,288,611 shares of the biotechnology company’s stock valued at $675,505,000 after acquiring an additional 1,488,552 shares in the last quarter. Norges Bank acquired a new position in BioMarin Pharmaceutical during the 4th quarter valued at about $447,572,000. AQR Capital Management LLC boosted its stake in BioMarin Pharmaceutical by 12.7% during the 4th quarter. AQR Capital Management LLC now owns 6,686,916 shares of the biotechnology company’s stock valued at $395,197,000 after purchasing an additional 754,807 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its holdings in BioMarin Pharmaceutical by 14.5% during the 1st quarter. Dimensional Fund Advisors LP now owns 3,802,930 shares of the biotechnology company’s stock worth $214,804,000 after purchasing an additional 481,176 shares in the last quarter. Institutional investors and hedge funds own 98.71% of the company’s stock.

More BioMarin Pharmaceutical News

Here are the key news stories impacting BioMarin Pharmaceutical this week:

• Positive Sentiment: BioMarin agreed to acquire Alesta Therapeutics for $275 million upfront, plus potential development and regulatory milestone payments. The deal gives BioMarin ALE1, a clinical-stage program that could become the first oral treatment for hypophosphatasia, a rare skeletal disease with significant unmet need. The asset could broaden BioMarin’s rare-disease pipeline and expand its exposure to larger patient markets. BioMarin to Acquire Alesta Therapeutics
• Positive Sentiment: Wedbush said the Alesta transaction strengthens BioMarin’s long-term growth outlook, reinforcing the view that ALE1 could provide a strategically attractive growth opportunity beyond the company’s existing commercial portfolio. BioMarin Pharmaceutical’s Alesta Deal Strengthens Long-Term Growth Outlook
• Positive Sentiment: Piper Sandler raised its BioMarin price target to $88 from $82 and maintained an overweight rating. Barclays also lifted its target to $111 from $105 and retained an overweight rating, reflecting substantial expected upside based on their models.
• Neutral Sentiment: HC Wainwright lowered its price target to $59 from $60 and assigned a neutral rating. The revised target implies downside from the current trading level, highlighting that some analysts view the shares as fully valued despite the pipeline opportunity.
• Neutral Sentiment: Recent coverage has also focused on BioMarin’s raised 2026 outlook and an ESOP shelf offering. The outlook may support investor confidence, while the offering introduces a potential capital-structure consideration that investors will monitor.

BioMarin Pharmaceutical Trading Up 0.5%

Shares of BMRN stock opened at $66.99 on Wednesday. BioMarin Pharmaceutical has a 1-year low of $49.26 and a 1-year high of $70.98. The company has a current ratio of 2.39, a quick ratio of 1.32 and a debt-to-equity ratio of 0.56. The stock has a market cap of $12.97 billion, a price-to-earnings ratio of 181.05, a PEG ratio of 0.47 and a beta of 0.24. The stock has a 50-day moving average of $59.94 and a 200-day moving average of $57.65.

BioMarin Pharmaceutical (NASDAQ:BMRN) last announced its earnings results on Thursday, August 6th. The biotechnology company reported $1.20 EPS for the quarter, beating the consensus estimate of $0.95 by $0.25. The business had revenue of $989.71 million for the quarter, compared to analysts’ expectations of $932.03 million. BioMarin Pharmaceutical had a return on equity of 5.32% and a net margin of 2.14%.The firm’s revenue was up 20.0% on a year-over-year basis. During the same period in the prior year, the business posted $1.44 earnings per share. BioMarin Pharmaceutical has set its FY 2026 guidance at 4.900-5.100 EPS. On average, equities research analysts forecast that BioMarin Pharmaceutical will post 4.12 earnings per share for the current year.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.